CLAIMS

1. Use of a sole parenteral composition comprising arginine, carbidopa and levodopa in the manufacture of a medicament for the treatment of Parkinson's disease, wherein the medicament is to be administered subcutaneously and in combination with an oral composition comprising a catechol-O-methyl transferase (COMT) inhibitor.

2. The use according to claim 1, wherein said sole parenteral composition is suitable for continuous administration.

3. The use according to claim 1, wherein said sole parenteral composition has a molar ratio of carbidopa and levodopa to arginine of 1:2 to 1:3.5.

4. The use according to claim 3, wherein said sole parenteral composition comprises (i) arginine, 0.1% to 2% by weight carbidopa, and 4% to 8% by weight levodopa; or (ii) arginine, 0.6% to 1.5% by weight carbidopa, and 6% by weight levodopa.

5. The use according to claim 3, wherein said sole parenteral composition comprises arginine, 0.1% to 2% by weight carbidopa, and 4% to 8% by weight levodopa.

6. The use according to claim 4 or 5, wherein the sole parenteral composition is to be administered at a rate of 0.1 to 1000 µl/h/site; or at a volume of 2 to 10 ml/24h/site; or at a dose of 80 to 800 mg levodopa/day and 20 to 200 mg carbidopa/day; or at a rate of 240 to 360 mg levodopa and 60 to 90 mg carbidopa/day/site.

7. The use according to claim 4 or 5, wherein said sole parenteral composition is to be administered at a volume of 4 to 6 ml/24h/site.

8. The use according to claim 3, wherein said sole parenteral composition comprises (i) arginine, 1% to 4% by weight carbidopa, and 6% to 16% by weight levodopa; or (ii) arginine, 1.5% to 2.5% by weight carbidopa, and 12% by weight levodopa.

9. The use according to claim 8, wherein said sole parenteral composition is to be administered at a rate of 0.2 to 2000 µl/h/site; or at a volume of 10 to 24 ml/24h/site; or at a dose of 600 to 4000 mg levodopa/day and 60 to 500 mg carbidopa/day; or at a rate of 800 to 1600 mg levodopa and 200 to 400 mg carbidopa/day/site.

10. The use according to claim 9, wherein said sole parenteral composition is to be administered at a volume of 12 to 16 ml/24h/site.

11. The use according to any one of claims 1 to 10, wherein the COMT inhibitor is entacapone or tolcapone.

12. The use according to claim 11, wherein the COMT inhibitor is entacapone.

13. The use according to claim 12, wherein the entacapone is to be administered two times per day at a dose of 400 mg.

14. The use according to any one of claims 1-13, wherein the sole parenteral composition is a liquid composition.